Abstract

BackgroundWe have developed an approach for modelling the health impact of introducing new smoke-free tobacco products. We wished to compare its estimates with those of alternative approaches, when applied to snus, used in Sweden for many years.MethodsModelling was restricted to men aged 30–79 years for 1980–2009 and to four smoking-related diseases. Mortality data were extracted for Sweden and other European countries. Published data provided Swedish prevalence estimates for combinations of never/former/current smoking and snus use, and smoking prevalence estimates for other European countries. Approach 1 compares mortality in Sweden and in other countries with a smoking prevalence similar to Sweden’s prevalence of combined smoking/snus use. Approaches 2 and 3 compare mortality in Sweden with hypothetical mortality had snus users smoked. Approach 3 uses our health impact model, individuals starting with the tobacco prevalence of Sweden in 1980. Tobacco histories during 30-year follow-up were then estimated using transition probabilities, with risk derived using a negative exponential model. Approach 2 uses annual tobacco prevalence estimates coupled with estimates of relative risk of current and former smokers regardless of history. The main applications of Approaches 2 and 3 assume that only smoking affects mortality, though sensitivity analyses using Approach 3 allow for risk to vary in snus users and dual users.ResultsUsing Approach 2, estimated mortality increases in Sweden in 1980–2009 had snus not been introduced were: lung cancer 8786; COPD 1781; IHD 10,409; stroke 1720. The main Approach 3 estimates were similar (7931, 1969; 12,501; 1901). They decreased as risk in snus users and dual users increased. Approach 1 estimates differed wildly (77,762, 32,538; 77,438; 76,946), remaining very different following correction for differences between Sweden and the comparison countries in non-smoking-related disease mortality.ConclusionsApproach 1 is unreliable, accounting inadequately for non-tobacco factors affecting mortality. Approaches 2 and 3 provide reasonably similar approximate estimates of the mortality increase had snus not been available, but have differing advantages and disadvantages. Only Approach 3 considers tobacco history, but develops histories using tobacco transition probabilities, which is possibly less reliable than using estimated tobacco prevalences at each follow-up year.

Highlights

  • We have developed an approach for modelling the health impact of introducing new smoke-free tobacco products

  • In 2015, we developed an approach to assess the population health impact of introducing a smoke-free tobacco product (SFTP) [2], leading to estimates of the impact of such introduction in the US on mortality from the four main smoking-related diseases (SRDs) – lung cancer, chronic obstructive pulmonary disease (COPD), ischaemic heart disease (IHD) and stroke [3, 4]

  • Three approaches have been investigated in an attempt to determine the increase in the number of deaths from lung cancer, COPD, IHD and stroke that might have occurred in Swedish men in 1980–2008 if snus had not been available

Read more

Summary

Introduction

We have developed an approach for modelling the health impact of introducing new smoke-free tobacco products. Based on (a) the tobacco histories obtained, (b) published estimates of the relative risk for current smoking and of the quitting half-life (the time it takes to halve the excess risk associated with continued smoking) [3], and (c) estimates of the effective dose (compared to cigarette only smokers) for SFTP only and for dual use, a negative exponential model (NEM) [3, 5] is used to estimate each individual’s risk of each disease at each year of follow-up Combining these estimates with national data on population size and mortality, one can derive the expected numbers of deaths in each Scenario and the reduction in the number of deaths related to introducing the SFTP

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call